Home
Storia in 1 fonti
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study - AstraZeneca (NYSE:AZN
AstraZeneca reports updated SERENA-6 data showing camizestrant improved PFS, PFS2 and ctDNA clearance in advanced breast cancer.
Raccontata da
benzinga.com
Timeline cronologica
- ·
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial - AstraZeneca (NYSE:AZN)
AstraZeneca's EMERALD-3 trial shows improved progression-free survival with STRIDE, lenvatinib and TACE in liver cancer.
- ·
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study - AstraZeneca (NYSE:AZN
AstraZeneca reports updated SERENA-6 data showing camizestrant improved PFS, PFS2 and ctDNA clearance in advanced breast cancer.